Back to top
more

Cytokinetics, Incorporated (CYTK)

(Real Time Quote from BATS)

$6.59 USD

6.59
304,055

+0.10 (1.54%)

Updated Nov 16, 2018 09:42 AM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.32%
18.25%
9.79%
5.22%
2.14%
10.57%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | C Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of 24.53% and 377.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CYTK

Zacks Equity Research

Cytokinetics (CYTK) Q3 Earnings Preview: What to Know Ahead of the Release

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CYTK

Zacks Equity Research

Cytokinetics (CYTK) Q3 Earnings Preview: What to Watch Ahead of the Release

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CYTK

Zacks Equity Research

Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?

Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.

CYTK

Arpita Dutt

Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

CELG ACOR BIIB CYTK

Zacks Equity Research

Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?

Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.

CYTK

Zacks Equity Research

Implied Volatility Surging for Cytokinetics (CYTK) Stock Options

Cytokinetics (CYTK) needs Investors to pay close attention to the stock based on moves in the options market lately.

CYTK

Zacks Equity Research

Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock

Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.

CYTK

Zacks Equity Research

New Strong Sell Stocks for May 4th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

DNBF FRTA CYTK

Zacks Equity Research

ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y

ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.

CYTK IMGN CLLS SNSS

Zacks Equity Research

Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up

Agios Pharmaceuticals, Inc. (AGIO) posted fourth-quarter 2016 loss of $1.34 per share, narrower than the Zacks Consensus Estimate of a loss of $1.55 but wider than the year-ago loss of $1.08.

CELG CYTK AGIO SNSS

Zacks Equity Research

Kura Oncology (KURA) Catches Eye: Stock Jumps 6.8%

Kura Oncology (KURA) saw its shares rise almost 7% in the last trading session.

CYTK KURA

Zacks Equity Research

Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4

Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.

ACOR CYTK CLLS SNSS

Zacks Equity Research

Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI

Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI

MCRN RMP CVGW CYTK

Zacks Equity Research

Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)

Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

GILD CYTK

Zacks Equity Research

5 Profitability Stocks to Make the Most of Trump Bump

Net income ratio selects the best profitable company on the back of Trump-led rally.

CVGW IIVI CYTK

Zacks Equity Research

3 Reasons Why Cytokinetics (CYTK) is a Great Momentum Stock

Cytokinetics (CYTK) may prove to be a fresh pick that has potential to move in the right direction and is seeing momentum.

CYTK

Zacks Equity Research

Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife

Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife

CVGW CYTK SCMP

Zacks Equity Research

Cytokinetics (CYTK): An Off-the-Radar Potential Winner

Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for Cytokinetics (CYTK) and that now might be an interesting buying opportunity.

CYTK

Zacks Equity Research

5 Profitable Stocks to Buy for Great Returns

Net income ratio gives us the exact profit level of a company and reflects the percentage of net income to total sales revenue.

CVGW CRY CYTK SCMP

Tirthankar Chakraborty

New Strong Buy Stocks for December 28th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

BPMC AKBA CYTK FFKT

Zacks Equity Research

3 Biotech Stocks to Turn the Tide This Earnings Season

The biotech sector has strong fundamentals, and healthy product pipelines.

ACOR NKTR CYTK

Zacks Equity Research

4 Biotech Stocks Looking Good this Earnings Season

the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.

GILD BIIB CYTK

David Bartosiak

5 Stocks Rocketing to New Highs

These 5 stocks are breaking out to new highs on good volume

VC MEET ATHN CYTK